clinical development

Atossa Therapeutics reported Q1 2026 expenses of $9.9M, secured FDA orphan drug designation for lead candidate (Z)-endoxifen in rare diseases.

Assembly Biosciences reports Q1 2026 results with $226.6M cash runway into 2028, completing Phase 1b herpes studies and advancing hepatitis delta candidate toward Phase 2.

Incannex Healthcare wins MedTech Breakthrough Award for IHL-42X sleep apnea therapy, validated by successful Phase 2 trial results showing significant improvements in key endpoints.

Biotech firm Immutrin appoints Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary to advance amyloidosis antibody therapy toward clinical trials.

TScan Therapeutics reports $28.7M Q1 loss, $1.0M revenue; $128.1M cash funds operations to H2 2027 amid Phase 3 pipeline advancement.

Nanjing Leads Biolabs and Dianthus Therapeutics advance LBL-047, a bifunctional fusion protein, into Phase 1 trials for three autoimmune conditions with $719M in funding.

Relmada to present NDV-01 Phase 2 data showing 76% response rate in bladder cancer at AUA 2026 conference; Phase 3 registration trial launches mid-2026.

Gyre Therapeutics completes all-stock acquisition of Cullgen for ~$300M, creating integrated biopharmaceutical company with U.S.-China operations and commercial-stage fibrosis drug.

Molecular Partners will present its DLL3-targeting Radio-DARPin candidate MP0712 at three major scientific conferences in May 2026, highlighting early clinical trial data.

ProQR Therapeutics nominates Boehringer Ingelheim's Chief Medical Officer Dr. Lykke Hinsch Gylvin to its Board, pending shareholder approval.

Exicure partners with Korea's Adbiotech on co-development of Burixafor for sickle cell disease, leukemia, and solid tumors, targeting IND studies and clinical trials.

Maze Therapeutics prices $150M offering at $23.50/share, securing funding through 2029 for kidney disease and PKU programs.

Revolution Medicines closes $2.2B concurrent offerings, including equity and convertible notes, to accelerate drug development and commercialization.

Aligos Therapeutics licenses pevifoscorvir to Xiamen Amoytop for Greater China development, receiving $25M upfront and up to $420M in milestones.

Alethio Therapeutics unveils ATX-011, a first-in-class antibody for treating Essential Thrombocythemia, with IND submission targeted for Q1 2027 and clinical data expected H1 2028.

Revolution Medicines raises $2.0 billion via 10.56M shares at $142/share and $500M convertible notes for R&D and commercialization.

Epitopea appoints Dr. Lisa Butterfield, immuno-oncology expert, to Scientific Advisory Board to advance RNA-based cancer immunotherapies.

Zymeworks names permanent R&D and business development leaders, strengthening governance and strategic execution as it advances its clinical pipeline and asset aggregation strategy.

Fortrea unveiled Fortrea Intelligent Technology, an AI-driven solution suite designed to automate workflows and provide real-time insights across clinical trial operations.

BioCryst appoints experienced pharma executive Sandeep Menon as Chief R&D Officer, bolstering leadership as it advances navenibart toward FDA approval.